ABOUT

It takes 10–15 years and 2 Billion $ to bring a single new drug to the patients. About 1 Billion $ (i.e. 50% of the total expense) is spent on Clinical Trials. More than 90% of the compounds that enter the Clinical Trial stage FAIL to advance to regulatory approval. This trend of high failure rates has been observed for decades and is still ongoing.

Our mission is to improve the highly primitive and slow Clinical Trial process through the use of big data and AI algorithms. We are building softwares that will provide fast and accurate insights which when implemented can change the trajectory of your Clinical Trials towards success.

Our first product evaluates clinical trial study design (that defines patient characteristics to be included in the study and the clinical outcomes after a drug has been administered) and improves the design reducing design amendments and de-risking the trial execution.

TEAM

Founded by a physician-scientist and AI expert duo whose ambition is to save time and cost of clinical trials, getting  the drug to the market faster and improving the morbidity and mortality of patients awaiting a new drug.